Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer Taps Gubra For Early-Stage Obesity Deal

Executive Summary

Boehringer Ingelheim has signed a collaboration with Denmark-based Gubra focusing on the development of peptides to treat obesity, with Gubra to receive up to €250m in upfront and potential milestone payments.

Advertisement

Related Content

Deal Watch: AstraZeneca Offloads US Anesthesiology Portfolio To Aspen
Jardiance Joy Boosts Boehringer Ingelheim
BI/Lilly's Jardiance Is First Diabetes Drug With CV Benefit Claim
Novo's Saxenda bags FDA approval for weight management
Lilly/BI biosimilar Lantus approved in Europe

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC099451

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel